U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 151 - 160 of 179 results

Status:
US Previously Marketed
Source:
KANAMYCIN SULFATE by FRESENIUS KABI USA
(2002)
Source URL:
First approved in 1958
Source:
Kantrex by Bristol
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Kanamycin A is aminoglycoside anti-bacterial agent. Active against many strains of Gram-negative bacteria and Gram-positive Staphylococcus aureus and epidermis. Some strains of Mycobacterium bacterium are sensitive. Most active in alkaline solution. It binds to bacterial ribosomes and reduces mRNA translation hence reduces protein biosynthesis. However, it also exhibits some toxic effects towards mammalian cells.
Status:
US Previously Marketed
Source:
KANAMYCIN SULFATE by FRESENIUS KABI USA
(2002)
Source URL:
First approved in 1958
Source:
Kantrex by Bristol
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Kanamycin A is aminoglycoside anti-bacterial agent. Active against many strains of Gram-negative bacteria and Gram-positive Staphylococcus aureus and epidermis. Some strains of Mycobacterium bacterium are sensitive. Most active in alkaline solution. It binds to bacterial ribosomes and reduces mRNA translation hence reduces protein biosynthesis. However, it also exhibits some toxic effects towards mammalian cells.
Status:
US Previously Marketed
Source:
KECTIL DIHYDROSTREPTOMYCIN SULFATE by BRISTOL LABS
(1961)
Source URL:
First approved in 1948
Source:
Dihydrostreptomycin Sulfate by Merck
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Dihydrostreptomycin is an antibiotic compound derived from streptomycin by reduction with hydrogen. The primary mechanism of action of the antibiotic dihydrostreptomycin is binding to and modifying the function of the bacterial ribosome, thus leading to decreased and aberrant translation of proteins, in addition it binds mechanosensitive channel of large conductance (MscL) and modifies its conformation, thus allowing the passage of K+ and glutamate out of, and dihydrostreptomycin into, the cell. It has about the same degree of antibacterial activity as streptomycin, but it is less effective against some gram-negative microorganisms. Because it has a higher risk of irreversible deafness, and its effectiveness is no greater that that of streptomycin, dihydrostreptomycin is no longer used clinically. To date dihydrostreptomycin is approved for veterinary use to treat bacterial infections.
Status:
US Previously Marketed
Source:
KECTIL DIHYDROSTREPTOMYCIN SULFATE by BRISTOL LABS
(1961)
Source URL:
First approved in 1948
Source:
Dihydrostreptomycin Sulfate by Merck
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Dihydrostreptomycin is an antibiotic compound derived from streptomycin by reduction with hydrogen. The primary mechanism of action of the antibiotic dihydrostreptomycin is binding to and modifying the function of the bacterial ribosome, thus leading to decreased and aberrant translation of proteins, in addition it binds mechanosensitive channel of large conductance (MscL) and modifies its conformation, thus allowing the passage of K+ and glutamate out of, and dihydrostreptomycin into, the cell. It has about the same degree of antibacterial activity as streptomycin, but it is less effective against some gram-negative microorganisms. Because it has a higher risk of irreversible deafness, and its effectiveness is no greater that that of streptomycin, dihydrostreptomycin is no longer used clinically. To date dihydrostreptomycin is approved for veterinary use to treat bacterial infections.
Status:
US Previously Marketed
Source:
KECTIL DIHYDROSTREPTOMYCIN SULFATE by BRISTOL LABS
(1961)
Source URL:
First approved in 1948
Source:
Dihydrostreptomycin Sulfate by Merck
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Dihydrostreptomycin is an antibiotic compound derived from streptomycin by reduction with hydrogen. The primary mechanism of action of the antibiotic dihydrostreptomycin is binding to and modifying the function of the bacterial ribosome, thus leading to decreased and aberrant translation of proteins, in addition it binds mechanosensitive channel of large conductance (MscL) and modifies its conformation, thus allowing the passage of K+ and glutamate out of, and dihydrostreptomycin into, the cell. It has about the same degree of antibacterial activity as streptomycin, but it is less effective against some gram-negative microorganisms. Because it has a higher risk of irreversible deafness, and its effectiveness is no greater that that of streptomycin, dihydrostreptomycin is no longer used clinically. To date dihydrostreptomycin is approved for veterinary use to treat bacterial infections.
Status:
US Previously Marketed
Source:
KECTIL DIHYDROSTREPTOMYCIN SULFATE by BRISTOL LABS
(1961)
Source URL:
First approved in 1948
Source:
Dihydrostreptomycin Sulfate by Merck
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Dihydrostreptomycin is an antibiotic compound derived from streptomycin by reduction with hydrogen. The primary mechanism of action of the antibiotic dihydrostreptomycin is binding to and modifying the function of the bacterial ribosome, thus leading to decreased and aberrant translation of proteins, in addition it binds mechanosensitive channel of large conductance (MscL) and modifies its conformation, thus allowing the passage of K+ and glutamate out of, and dihydrostreptomycin into, the cell. It has about the same degree of antibacterial activity as streptomycin, but it is less effective against some gram-negative microorganisms. Because it has a higher risk of irreversible deafness, and its effectiveness is no greater that that of streptomycin, dihydrostreptomycin is no longer used clinically. To date dihydrostreptomycin is approved for veterinary use to treat bacterial infections.
Phenylmercuric borate is classified as antimicrobial preservative. It is bactericidal against many Gram-positive and Gram-negative species. Fungicidal activity has been demonstrated against Candida albicans and Aspergillus niger. Phenylmercuric borate (PHB) is very rapidly incorporated into the cells of Escherichia coli. On the membrane, an important part of PHB seems to be associated with the ribosomes and particularly to the ribosomal proteins. Phenylmercuric borate solution is indicated for the treatment of tonsillitis, otitis, vulvovaginitis, furuncles, anthrax and ulcers, pyoderma, impetus, gingivitis and stomatitis. The regular hand disinfection with a liquid soap containing phenylmercuric borate enhanced urinary excretion of mercury indicating an increase in total daily absorption of the toxic metal. The additional amounts of mercury absorbed through the use of mercury contained in skin disinfectants are potentially dangerous for human.
Phenylmercuric borate is classified as antimicrobial preservative. It is bactericidal against many Gram-positive and Gram-negative species. Fungicidal activity has been demonstrated against Candida albicans and Aspergillus niger. Phenylmercuric borate (PHB) is very rapidly incorporated into the cells of Escherichia coli. On the membrane, an important part of PHB seems to be associated with the ribosomes and particularly to the ribosomal proteins. Phenylmercuric borate solution is indicated for the treatment of tonsillitis, otitis, vulvovaginitis, furuncles, anthrax and ulcers, pyoderma, impetus, gingivitis and stomatitis. The regular hand disinfection with a liquid soap containing phenylmercuric borate enhanced urinary excretion of mercury indicating an increase in total daily absorption of the toxic metal. The additional amounts of mercury absorbed through the use of mercury contained in skin disinfectants are potentially dangerous for human.
Tylvalosin (TVS) is a third-generation macrolide drug used for prophylaxis and treatment of mycoplasma. Tylvalosin, the active ingredient of Aivlosin 625 mg/g Water Soluble Granules (ECO Animal Health, UK), is a modern macrolide that has shown its effectiveness in the control of porcine proliferative enteropathy, EP and swine dysentery. Aivlosin is indicated for the control of porcine proliferative enteropathy (PPE) associated with Lawsonia intracellularis infection in groups of swine in buildings experiencing an outbreak of PPE. Tylvalosin tartrate is a macrolide antibiotic that has antibacterial activity against Gram-positive, some Gram-negative organisms and mycoplasma. It acts by inhibiting protein synthesis in the bacteria cell.
Tiamulin is a diterpene antimicrobial with a pleuromutilin chemical structure similar to that of valnemulin. The activity of tiamulin is largely confined to gram-positive micro-organisms and mycoplasma. Tiamulin acts by inhibiting protein synthesis at the ribosomal level. In veterinary medicine, tiamulin is used for treatment and prophylaxis of dysentery, pneumonia and mycoplasmal infections in pigs and poultry. Tiamulin is available as a 2, 10 or 20% premix for pigs and poultry, a 12.5% solution or 45% water soluble powder for addition to drinking water for pigs and poultry, or a 10% injectable formulation for pigs. Tiamulin inhibits protein synthesis by targeting the 50S bacterial ribosomal subunit and binding to peptidyl transferase, the enzyme responsible for forming peptide bonds between amino acids.

Showing 151 - 160 of 179 results